Kepler Capital analyst Oliver Reinberg maintained a Hold rating on Qiagen (NYSE:QGEN) NV on Thursday, setting a price target of EUR39, which is approximately 8.98% below the present share price of $42.85.
Reinberg expects Qiagen NV to post earnings per share (EPS) of $0.17 for the second quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Hold rating of shares in Qiagen, with an average price target of $39.65.
The analysts price targets range from a high of $42.2 to a low of $30.3.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $372.1 million and a net profit of $79.68 million. The company's market cap is $9.65 billion.
According to TipRanks.com, Kepler Capital analyst Oliver Reinberg 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.8% and a 42.4% success rate.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
